ebook Munafa Stock Market Course + Intraday & FNO calls  

       

Outlook Therapeutics (OTLK) Technical (Analysis) Reports Outlook Therapeutics ["Technical Analysis"] Reports -NASDAQ Stock Exchange MunafaSutra.com

Complete & easy to understand technical analysis of Outlook Therapeutics (OTLK)

Technical Analysis Report for NASDAQ stock OTLK Outlook Therapeutics. Dated: 29 May 2026 Updated Daily. Stock trades under Health Care Deals in Biotechnology Biological Products No Diagnostic Substances in NASDAQ stock exchange

If you are looking for Tomorrow's Movement Predictions for NASDAQ stock OTLK Outlook Therapeutics then click here. or read Experts views on Outlook Therapeutics or Forecast & share price targets of Outlook Therapeutics

Outlook Therapeutics Opened at 0.75 and Closed at: 0.73, which is -1.37% of previous session's close. It moved within a range of 0.68 and 0.82
The session was a Bearish session with an average volume of 30554368, which is -240.34% of previous session's volumes.

  • Even though the stock has fallen, but its short term trend is positive and in an uptrend.

A Golden cross was found 5 days back on short term averages

A Golden cross was found 4 days back on mid term averages

Support for tomorrow is 0.64 and resistance for tomorrow is 0.78
These support and resistance points are valid for the first 5-15 minutes charts

Above are simple pivot point calculations. For a list of much stronger support and resistance levels click here. These are way more stronger support and resistance levels, and mark trend reversals and are Support & Resistance levels recommended by experts.

Support for tomorrow's hourly charts is 0.67, 0.6 resistance for tomorrow's hourly charts is 0.81, 0.88

10 Day SMA for Outlook Therapeutics (OTLK) is 0.41 and stock is trading above these levels. This is a good sign for its short term trend

20 Day SMA for Outlook Therapeutics (OTLK) is 0.32 and the stock is trading above these levels. This is a good sign for its mid term trend

50 Day SMA for Outlook Therapeutics (OTLK) is 0.28 and the stock is trading above these levels. This is a good sign for its mid to long term trend

100 Day SMA is 0.37 and the stock is trading above these levels. This is a good sign for its long term trend

200 Day SMA Outlook Therapeutics is 0.94 and stock is trading below these levels. This is not a good sign for its long term trend

20 DMA of Outlook Therapeutics is at 0.32 and 200 DMA is at 0.94, while 50 DMA and 100 DMA are at 0.28 and 0.37 respectively

Outlook Therapeutics (OTLK) moving average of 20 SMA is at 0.32 and 20 EMA is at 0.4

Outlook Therapeutics (OTLK) moving average of 50 SMA is at 0.28 and 50 EMA is at 0.38

Outlook Therapeutics (OTLK) moving average of 100 SMA is at 0.37 and 100 EMA is at 0.49

Outlook Therapeutics (OTLK) moving average of 200 SMA is at 0.94 and 200 EMA is at 0.81

Outlook Therapeutics has performed better than Vertex Pharmaceuticals in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Veru Inc in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Prothena Corporation in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Medicinova Inc in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Lexicon Pharmaceuticals in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Ligand Pharmaceuticals in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Agenus Inc in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Altimmune Inc in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Amarin Corporation in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Array Biopharma in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Assertio Therapeutics in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Biogen Inc in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Benitec Biopharma in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Editas Medicine in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Gossamer Bio in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Hutchison China in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics has performed better than Immutep in short term. Holding Outlook Therapeutics could be a better choice for now!

Outlook Therapeutics Technical analysis of indicators

Price action analysis of Outlook Therapeutics (OTLK) based on a short term time period is definitely positive! This means that there is a strong uptrend in the stock for the given time period. Buyers are extremely bullish on the stock.

ADX buy sell signal for Outlook Therapeutics stock for short term is BUY. Signal strength is Weak and stock is losing momentum.

MACD generated a BUY signal for Outlook Therapeutics in short term and the buy signal is strong.

MACD line is moving upwards which means that SELL signal is weakening, and buying is picking up momentum.

Outlook Therapeutics Stock is trading near its recent HIGHS, which reflects strong buying momentum in short term! Bulls are getting stronger in this stock.

Ichimoku cloud is of green color and prices are above the green cloud Prices appear to be coming down

CCI has generated a buy signal for Outlook Therapeutics in short term and BUY signal is strong.

RSI is generating a BUY signal in short term and the buying is gaining momentum.

MRSI is in negative zone. This is the SELL zone

Although the stock is in the SELL zone, but selling might be slowing down

Stock of Outlook Therapeutics is picking up selling momentum according to indicator.

Volume based indicators are showing selling momentum.

Volume Weighted Averaged Price (VWAP) for short term is 0.49 and Outlook Therapeutics OTLK stock is trading above this level. This is a good sign for the stock and it could move higher. VWAP is rising upwards.

People seem to be coming out and selling the Outlook Therapeutics OTLK stock. Volume based technical analysis of Outlook Therapeutics OTLK stock is negative.

Outlook Therapeutics Stock is giving positive returns over a short term period. Returns for a longer term period have been positive

Force Index is moving in a negative zone, which indicates selling momentum for short term... Selling momentum is getting weaker.

Tomorrow's Predictions

You should also read Tomorrow's Movement Predictions for NASDAQ stock OTLK Outlook Therapeutics These predictions are based on various factors, are easy to understand, and upto 75% accurate!

And OTLK Experts View which covers a lot of information including buying and selling signals

OTLK future forecast & share price targets

You can also take a look at the Charts and indicator analysis here Announcements & NEWS by Outlook Therapeutics or View Candle Stick Charts here

Chart Outlook Therapeutics (OTLK)  Technical (Analysis) Reports Outlook Therapeutics [

Videos related to: Outlook Therapeutics (OTLK) Technical (Analysis) Reports Outlook Therapeutics ["Technical Analysis"] Reports -NASDAQ Stock Exchange MunafaSutra.com

Hindi Basics How To Trade In FnO Futures Options Stock Market

Hindi Video The Truth Of Stock Markets That Everyone Is Hiding From You

Outlook Therapeutics (OTLK)  Technical (Analysis) Reports Outlook Therapeutics [

 

Back to top